TheEdgeResearch
Home / Stocks / BFRI

Biofrontera Inc. (BFRI)

NASDAQ Healthcare Medical - Pharmaceuticals
$1.22 ▲ +0.83%
Market Cap
$15.6M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.80
52-Wk Range
0.555-1.27
CEO
Hermann Lübbert
Country
US
Currency
USD

Biofrontera Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Woburn, MA, US. The stock last traded at $1.22, up 0.83% on the session, giving a market capitalisation of $15.6M. On trailing twelve-month figures it carries a trailing P/E of -1.09, a net margin of -25.7%. Its beta of 0.80 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.09
Price / Sales
0.36
Price / Book
2.35
EV / EBITDA
-1.70
Gross margin
82.8%
Operating margin
-20.6%
Net margin
-25.7%
Return on equity
Debt / equity
1.27
Current ratio
1.20
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
89
IPO date
2021-10-29
Headquarters
Woburn, MA, US
About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Comparable companies

Biofrontera Inc. is most often compared with the following Healthcare names:

AYTUCOCPDWTXEVGNGELSIMNNPRPHSBFMSNSETRIB
More research on BFRI
BFRI technical analysis BFRI TheEdge Score Compare against peers
Open full interactive analysis & DCF →